FILING ANALYSIS · MONDAY, NOVEMBER 9
Zentalis Pharmaceuticals, Inc. ZNTL — 8-K: Results of Operations and Financial Condition
neutral
Zentalis Pharmaceuticals reported its Q3 2026 financial results and business updates, including strengthened survival data for azenosertib and a cash runway into 1H 2028, but no quantified surprise or significant news that would move the stock beyond 1.5% in a week
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →